Healthcare provider profile · identity verified

Benjamin Chee, FNP

Nurse Practitioner · BRONX, NY · NPI 1730501354

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Diclofenac Sodium Er	Diclofenac Sodium	306	22
Doxepin Hcl	Doxepin Hcl	266	18
Atorvastatin Calcium	Atorvastatin Calcium	245	94
Amlodipine Besylate	Amlodipine Besylate	179	71
Albuterol Sulfate Hfa	Albuterol Sulfate	146	50
Gabapentin	Gabapentin	140	55
Metformin Hcl	Metformin Hcl	121	48
Furosemide	Furosemide	113	56
Levothyroxine Sodium	Levothyroxine Sodium	109	48
Omeprazole	Omeprazole	98	37
Metoprolol Succinate	Metoprolol Succinate	92	41
Losartan Potassium	Losartan Potassium	89	36
Lisinopril	Lisinopril	85	36
Vitamin D2	Ergocalciferol (Vitamin D2)	76	30
Pantoprazole Sodium	Pantoprazole Sodium	71	27
Fluocinonide	Fluocinonide	70	suppressed
Eliquis	Apixaban	62	23
Famotidine	Famotidine	62	27
Clotrimazole	Clotrimazole	58	15
Simvastatin	Simvastatin	58	27
Tamsulosin Hcl	Tamsulosin Hcl	58	28
Ibuprofen	Ibuprofen	55	23
Carvedilol	Carvedilol	52	26
Montelukast Sodium	Montelukast Sodium	51	19
Diclofenac Sodium	Diclofenac Sodium	48	22
Metoprolol Tartrate	Metoprolol Tartrate	48	22
Fluticasone Propionate	Fluticasone Propionate	47	16
Enalapril Maleate	Enalapril Maleate	46	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	43	18
Alcohol Prep Pads	Alcohol Antiseptic Pads	41	15
Azithromycin	Azithromycin	41	34
Januvia	Sitagliptin Phosphate	41	14
Donepezil Hcl	Donepezil Hcl	40	21
Jardiance	Empagliflozin	40	13
Novolog Flexpen	Insulin Aspart	40	12
Memantine Hcl	Memantine Hcl	39	19
Hydrochlorothiazide	Hydrochlorothiazide	38	17
Latanoprost	Latanoprost	38	12
Rosuvastatin Calcium	Rosuvastatin Calcium	38	19
Mirtazapine	Mirtazapine	37	15
Clopidogrel	Clopidogrel Bisulfate	36	16
Meclizine Hcl	Meclizine Hcl	36	18
Nystatin	Nystatin	36	14
Triamcinolone Acetonide	Triamcinolone Acetonide	33	11
Hydrocortisone	Hydrocortisone	32	suppressed
Sertraline Hcl	Sertraline Hcl	32	15
Tizanidine Hcl	Tizanidine Hcl	32	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	31	13
Azelastine Hcl	Azelastine Hcl	30	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	30	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	30	14
Prednisone	Prednisone	29	18
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	28	11
Escitalopram Oxalate	Escitalopram Oxalate	28	13
Ammonium Lactate	Ammonium Lactate	27	14
Ondansetron Hcl	Ondansetron Hcl	26	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	25	suppressed
Single Use Swab	Alcohol Antiseptic Pads	24	suppressed
Spironolactone	Spironolactone	24	suppressed
Oxycodone Hcl	Oxycodone Hcl	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Mupirocin	Mupirocin	22	12
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	21	16
Cephalexin	Cephalexin	21	19
Clonazepam	Clonazepam	21	suppressed
Etodolac	Etodolac	21	17
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Lidocaine	Lidocaine	21	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	21	suppressed
Nifedipine Er	Nifedipine	21	suppressed
Trazodone Hcl	Trazodone Hcl	21	12
Meloxicam	Meloxicam	20	suppressed
Ozempic	Semaglutide	20	suppressed
Allopurinol	Allopurinol	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Tramadol Hcl	Tramadol Hcl	19	suppressed
Finasteride	Finasteride	18	suppressed
Lorazepam	Lorazepam	18	suppressed
Ciclopirox	Ciclopirox Olamine	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	17
Linzess	Linaclotide	17	suppressed
Naproxen	Naproxen	17	suppressed
Bumetanide	Bumetanide	16	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Levofloxacin	Levofloxacin	16	suppressed
Nyamyc	Nystatin	16	suppressed
Alendronate Sodium	Alendronate Sodium	15	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	15	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	15	suppressed
Entresto	Sacubitril/Valsartan	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	15	suppressed
Naproxen Sodium	Naproxen Sodium	15	11
Risperidone	Risperidone	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Tradjenta	Linagliptin	14	suppressed
Baclofen	Baclofen	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Folic Acid	Folic Acid	13	suppressed
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Santyl	Collagenase Clostridium Hist.	13	suppressed
Alprazolam	Alprazolam	12	suppressed
Atenolol	Atenolol	12	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	12	suppressed
Glipizide	Glipizide	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Megestrol Acetate	Megestrol Acetate	12	suppressed
Scopolamine	Scopolamine	12	suppressed
Tresiba Flextouch U-200	Insulin Degludec	12	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	11	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Lumigan	Bimatoprost	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed
Vilazodone Hcl	Vilazodone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error